drugset / Trial / NCT00206661

Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease

NCT00206661

Phase 1/2 Terminated 22 enrolled Genzyme, a Sanofi Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to observe pediatric Crohn's Disease response to sargramostim in patients with or without steroid therapy at two possible dosage levels.

Timeline

Start
2004-12
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject sargramostim Protein / enzyme biologic 4 ug
Subject sargramostim Protein / enzyme biologic 6 ug

Indications